Literature DB >> 15795103

Physiological, pharmacological and clinical features of the multidrug resistance protein 2.

Olivier Fardel1, Emilie Jigorel, Marc Le Vee, Lea Payen.   

Abstract

Multidrug resistance protein 2 (MRP2, ABCC2) is a drug efflux pump belonging to the ATP-binding cassette (ABC) transporter superfamily. MRP2 is present predominantly at the biliary pole of hepatocytes and is also expressed in the kidney and intestine. It plays a major role in hepato-biliary elimination of many structurally diverse xenobiotics, including organic anions and drug conjugates, and therefore most likely contributes to pharmacokinetic parameters of these compounds. MRP2 also handles endogenous molecules such as bilirubin, and its overexpression has been shown to confer a multidrug resistance phenotype to tumoral cells. MRP2 expression can be regulated by endogenous substances such as inflammatory cytokines and biliary acids. The MRP2 levels and activity can also be affected by a large panel of xenobiotics, including chemopreventive agents and ligands of the pregnane X receptor, which may be a potential source of drug-drug interactions and drug adverse effects. MRP2 appears therefore as one of the major drug efflux pumps of the organism, whose functional and regulatory features are important to consider, notably for drug disposition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795103     DOI: 10.1016/j.biopha.2005.01.005

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  15 in total

1.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

Review 2.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

3.  Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2.

Authors:  Gilbert J Burckart; William D Figg; Maria M Brooks; Dionna J Green; Sarah M Troutman; Robert Ferrell; Richard Chinnock; Charles Canter; Linda Addonizio; Daniel Bernstein; James K Kirklin; David Naftel; Douglas K Price; Tristan M Sissung; Diana M Girnita; Adriana Zeevi; Steven A Webber
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

4.  Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).

Authors:  Vandana Megaraj; Tianyong Zhao; Christian M Paumi; Phillip M Gerk; Richard B Kim; Mary Vore
Journal:  Pharmacogenet Genomics       Date:  2011-08       Impact factor: 2.089

Review 5.  Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.

Authors:  Rossella Loria; Patrizia Vici; Francesca Sofia Di Lisa; Silvia Soddu; Marcello Maugeri-Saccà; Giulia Bon
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

6.  Transport of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, a metabolite of trichloroethylene, by mouse multidrug resistance associated protein 2 (Mrp2).

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Myong-Chul Koag; Debra Newman; Karoline Scholz; Galyna Bondar; Quansheng Zhu; Nuraly K Avliyakulov; Wolfgang Dekant; Kym Faull; Ira Kurtz; Alexander Pushkin
Journal:  Toxicol Appl Pharmacol       Date:  2010-01-06       Impact factor: 4.219

7.  Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter.

Authors:  Yasuo Uchida; Junichi Kamiie; Sumio Ohtsuki; Tetsuya Terasaki
Journal:  Pharm Res       Date:  2007-10-16       Impact factor: 4.200

8.  Hepatic expression of multidrug resistance protein 2 in biliary atresia.

Authors:  Keita Terui; Takeshi Saito; Tomoro Hishiki; Yoshiharu Sato; Tetsuya Mitsunaga; Hideo Yoshida
Journal:  Comp Hepatol       Date:  2011-08-03

9.  Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans.

Authors:  Isabelle Benz-de Bretagne; Renaud Respaud; Patrick Vourc'h; Jean-Michel Halimi; Agnès Caille; Jean-Sébastien Hulot; Christian R Andres; Chantal Le Guellec
Journal:  J Biomed Biotechnol       Date:  2011-03-14

10.  MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.

Authors:  Radosław Januchowski; Karolina Wojtowicz; Patrycja Sujka-Kordowska; Małgorzata Andrzejewska; Maciej Zabel
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.